Consent Preferences
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Other cookies are those that are being identified and have not been classified into any category as yet.

No cookies to display.

Antonio M. Echavarren obtains an ERC Advanced Grant

28th March 2019 – Antonio M. Echavarren, ICIQ group leader, has obtained a second Advanced Grant of € 2.5 million from the European Research Council (ERC) to develop new types of catalysts inspired by natural cyclase enzymes. His previous Advanced Grant (2013-2018) had focused on the discovery of new catalytic gold chemistry.

The project, entitled Catalytic Metallofoldamers of biological inspiration (Foldmetcat), aims to design and develop catalysts (molecules that intervene in the chemical reaction, increasing their speed without being consumed) that transform linear organic molecules into cyclic structures in a single step. The project has the potential to make more efficient the manufacture of drugs such as the anti-tumor taxol.

Screenshot 2019-03-28 at 12.04.15

The originality of the new project proposed by Echavarren has made it one of the selected projects out of a total of 2052 proposals presented in the call ERC-2018-AdG. Only one in ten projects submitted has been selected for funding – ten of the selected projects belong to Spanish institutions. This is the second Advanced Grant granted to Echavarren, who was recently also been awarded a Proof of Concept project for the development of efficient routes for the synthesis of polyacenes. With the new project, ICIQ adds a total of 19 ERC projects – seven currently in force.

Natural inspiration

“Nature is very wise, but that’s because it has had millions of years to optimize its processes. We intend to do something similar in five years,” smiles Echavarren. The project has a double objective. On the one hand, develop new types of artificial catalysts (polymetallic catalysts) that mimic the functions of the cyclase enzymes and obtain structurally complex molecules in a precise manner – in a single chemical transformation, as nature does. On the other hand, the research group wants to understand how to control cyclization processes to end up creating molecules with new architectures, which are not found in nature.

The research group will use the economic endowment to provide itself with the most advanced equipment for the analysis of complex mixtures, as well as for the computational work required for the design of artificial catalysts. “If this new strategy works, we will obtain artificial molecules [that are not found in nature] with the potential to develop new and more powerful drugs,” explains Echavarren.

Let's create a brighter future

Join our team to work with renowned researchers, tackle groundbreaking
projects and contribute to meaningful scientific advancements

Join us!
Board of Trustees:
Member of:
Accredited with:
With the support of: